Diagnosis and treatment of benign prostatic hyperplasia by general practitioners;UTREDNING OG BEHANDLING AV BENIGN PROSTATAHYPERPLASI I ALLMENNPRAKSIS

Tidsskrift for den Norske Laegeforening

Volumn 116, Issue 27, 1996, Pages 3240-3244

  Eri, Lars Magne ^a   Wahlqvist, Rolf ^a   Tveter, Kjell J ^a  

^a Urologisk Avdeling   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; GONADORELIN; INDORAMIN; PRAZOSIN; TERAZOSIN; URAPIDIL;

DIFFERENTIAL DIAGNOSIS; DRUG CHOICE; GENERAL PRACTITIONER; HUMAN; MALE; PROSTATE HYPERTROPHY; SHORT SURVEY; SYMPTOMATOLOGY;

DIAGNOSIS, DIFFERENTIAL; FAMILY PRACTICE; HUMANS; MALE; NORWAY; PROSTATIC HYPERPLASIA;

EID: 0029858663     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9.
2. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85-9.
3. Abrams P. New words for old: lower urinary tract symptoms for «prostatism». BMJ 1994; 308: 929-30.
4. Eri L, Tveter KJ. Measuring the quality of life of patients with benign prostatic hyperplasia. Assessment of the usefulness of a new quality of life questionnaire specially adapted to benign prostatic hyperplasia patients. Eur Urol 1992; 21: 257-62.
5. Tveter KJ, Otnes B. Klinisk betydning av prostataspesifikt antigen. Tidsskr Nor Lægeforen 1994; 114: 160.
6. Otnes B, Tveter KJ. Screening for tidlig diagnose av prostatacancer. Tidsskr Nor Lægeforen 1994; 114: 1105.
7. Eri LM, Tveter KJ. α-Blockade in the treatment of symptomatic benign prostatic hyperplacia. J Urol 1995; 154: 923-34.
8. Kaplan SA, Soldo KA, Olsson CA. Terazosin and Doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. Eur Urol 1995; 28: 223-8.
9. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-5.
10. Beistand HO, Binkowitz B, Brekkan E, Ekman E, Kontturi M, Lehtonen L et al. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992; 22: 271-7.
11. Andersen JT, Ekman P, WolfH, Beisland HO, Johansson JE, Kontturi M et al. Can finastende reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995; 46: 631-7.
12. Tveter KJ, Beisland HO, Andersen J Thorup, Wolf H, Ekman P, Johansson J-E et al. Behandling av benign prostatahyperplasi med Proscar (finasterid). Tidsskr Nor Lægeforen 1996; 116: 3226-30.
13. Boyle P, Gould AL. Prostate volum predicts outcome of treatment of BPH with finasteride. Meta-analysis of randomized clinical trials. J Urol 1996; 155: 572A.